Electroencephalography Markers of Brain Stimulation in Post-Concussion Patients (Stim-PPCS)
Identification of EEG Biomarkers Associated With Transcranial Direct Current Stimulation in Patients With Persistent Post-Concussion Symptoms
In this randomized, sham-controlled, two-group, parallel, single-session study, the investigators aim to identify EEG biomarkers associated with cerebellar transcranial direct current stimulation (tDCS) in patients with persistent post-concussion symptoms (PPCS). Cerebellar tDCS will be used to modulate brain network connectivity, which is known to be altered in PPCS. The study will include 38 participants, each completing a single session including EEG recordings before and after stimulation. Participants will be randomly assigned to one of two conditions: 1) active cerebellar tDCS, or 2) sham stimulation.By focusing on EEG functional connectivity and related signal metrics, this study aims to better understand the neural mechanisms of cerebellar tDCS and support the development of targeted interventions for patients with PPCS.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Nicolas Lejeune
- Numéro de téléphone: +32043232323
- E-mail: nicolas.lejeune@uliege.be
Lieux d'étude
-
-
Liege
-
Tinlot, Liege, Belgique, 4557
- Centre Neurologique et de réadaptation Fonctionnelle
-
Contact:
- Lejeune Nicolas
- Numéro de téléphone: +32043232323
- E-mail: nicolas.lejeune@uliege.be
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Be aged 18 years or older;
- Have received a medical diagnosis of concussion within the 12 months prior to recruitment;
- Exhibit persistent post-concussion symptoms (PPCS) with a score ≥16 on the Rivermead Post-Concussion Symptoms Questionnaire
Exclusion Criteria:
- Identified risk for tDCS exposure according to the Transcranial Direct Current Stimulation Safety Screening Tool
- Neurological or psychiatric disorders with a prior medical diagnosis that could alter brain network connectivity before the concussion
- Use of medications (antidepressants, anxiolytics, antipsychotics, antiepileptics) that may affect brain connectivity.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur actif: Active tDCS
Active tDCS participants will receive high-definition cerebellar transcranial direct current stimulation using a multi-electrode montage optimized to target bilateral cerebellar regions. The electrode configuration is identical across conditions and has been defined using computational modeling to maximize focality while limiting current spread to adjacent areas. The stimulation consists of a 30-second ramp-up phase, followed by 20 minutes of continuous stimulation, and a 30-second ramp-down phase. |
Transcranial direct current stimulation is a non-invasive brain stimulation technique that delivers a weak direct electrical current through scalp electrodes to modulate neuronal excitability (<2mA). Cerebellar tDCS will be administered using an 8-channel montage optimized with the Stimweaver software (Neuroelectrics, Barcelona, Spain) to maximize current density over the cerebellum while minimizing off-target effects. A constant direct current will be applied for 20 minutes, with a 30-second ramp-up at the beginning and a 30-second ramp-down at the end. Other Name: |
|
Comparateur factice: Sham tDCS
Sham tDCS participants will undergo the same high-definition cerebellar electrode montage as the active tDCS group, ensuring identical setup and participant experience. However, no sustained current is delivered to the scalp. The protocol includes brief ramp-up and ramp-down phases at the beginning and end of the session to mimic the sensations of real stimulation, while preventing any meaningful modulation of cortical excitability. This approach, established in previous studies, maintains blinding of participants to the stimulation condition. The investigator administering the stimulation will also be blinded, as the tDCS device allows double blinding, with identical screen displays in both sham and active conditions. |
Transcranial direct current stimulation is a non-invasive brain stimulation technique that delivers a weak direct electrical current through scalp electrodes to modulate neuronal excitability (<2 mA). The device used has a sham setting that allows sham stimulation to be delivered while the interventionist remains blinded.Other Name: |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
EEG Functional Connectivity in the Alpha Band (dwPLI)
Délai: EEG functional connectivity will be assessed at two time points: immediately before and immediately after the stimulation session.
|
EEG functional connectivity will be assessed using the debiased weighted Phase Lag Index (dwPLI) in the alpha frequency band (8-12 Hz). This metric quantifies the consistency of phase relationships between EEG signals across brain regions while minimizing the effects of volume conduction. It will be used to evaluate changes in large-scale brain network connectivity associated with cerebellar transcranial direct current stimulation (tDCS) in patients with persistent post-concussion symptoms (PPCS). Differences in connectivity patterns between pre- and post-stimulation recordings, as well as between active and sham groups, will be analyzed. |
EEG functional connectivity will be assessed at two time points: immediately before and immediately after the stimulation session.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Permutation entropy (PE)
Délai: Immediately before and immediately after the stimulation session
|
Permutation Entropy (PE) will be calculated from EEG signals to quantify the temporal irregularity and unpredictability of brain activity. PE is a dimensionless measure. |
Immediately before and immediately after the stimulation session
|
|
Normalized Lempel-Ziv Complexity (LZC)
Délai: Immediately before and immediately after the stimulation session
|
Normalized Lempel-Ziv Complexity (LZC) will be calculated from EEG signals to quantify the diversity and complexity of brain activity patterns. LZC is a dimensionless measure. |
Immediately before and immediately after the stimulation session
|
|
EEG microstate
Délai: Immediately before and immediately after the stimulation session
|
EEG microstate analysis will be conducted to examine temporal dynamics of large-scale brain networks. Metrics will include microstate duration, coverage, and occurrence. These will be computed from resting-state EEG recordings acquired before and after stimulation to explore modulation of brain network organization. |
Immediately before and immediately after the stimulation session
|
|
EEG spectral analysis (alpha peak and spectral slope)
Délai: Immediately before and immediately after the stimulation session
|
Spectral properties of EEG signals will be analyzed, including alpha peak frequency and spectral slope. These measures provide insight into oscillatory activity and excitation-inhibition balance. Analyses will be performed on resting-state EEG recordings collected pre- and post-intervention. |
Immediately before and immediately after the stimulation session
|
|
Phase-amplitude coupling
Délai: Immediately before and immediately after the stimulation session
|
Analyses will assess phase-amplitude coupling and coherence to evaluate cross-frequency interactions and synchronization between brain regions. These measures will be derived from resting-state EEG recordings before and after stimulation. |
Immediately before and immediately after the stimulation session
|
|
Alpha band participation coefficient
Délai: Immediately before and immediately after the stimulation session
|
The participation coefficient in the alpha band will be computed to assess the integration of brain regions within large-scale networks. This will be derived from resting-state EEG data collected pre- and post-intervention. |
Immediately before and immediately after the stimulation session
|
|
Rivermead Post-Concussion Symptoms Questionnaire
Délai: Pre-intervention (baseline)
|
Post-concussion symptoms will be assessed using the French version of the Rivermead Post-Concussion Symptoms Questionnaire (total score range: 0-64, with higher scores indicating greater symptom severity). This self-reported measure evaluates the severity of common post-concussion symptoms and will be used to characterize baseline symptom burden. |
Pre-intervention (baseline)
|
|
Simple Reaction Time Task
Délai: Pre-intervention and immediately post-intervention
|
Participants will complete a computerized simple reaction time task to assess processing speed and motor responsiveness. Performance will be compared before and after stimulation. |
Pre-intervention and immediately post-intervention
|
|
Sport concussion assessment tool 6 (SCAT6)
Délai: Pre-intervention and immediately post-intervention
|
The SCAT6 symptom evaluation (Step 2) will be used to assess immediate concussion-related symptoms (total score range: 0-132, with higher scores indicating greater symptom severity). This questionnaire will be administered before and after the intervention to explore changes in symptom severity. |
Pre-intervention and immediately post-intervention
|
|
Sustained Attention Task (TAP)
Délai: Pre-intervention and immediately post-intervention
|
A computerized cognitive task assessing attention will be administered pre- and post-intervention. Performance metrics will be analyzed to evaluate potential cognitive effects of the stimulation. |
Pre-intervention and immediately post-intervention
|
|
Blinding assessment
Délai: Immediately post-intervention
|
A blinding questionnaire will be completed by both the participant and the interventionist to assess the effectiveness of blinding between active and sham stimulation conditions. |
Immediately post-intervention
|
|
Adverse events reporting
Délai: Immediately post-intervention
|
Adverse events will be assessed using a standardized questionnaire as described in Reckow et al. This will capture any discomfort or side effects associated with the intervention. |
Immediately post-intervention
|
|
Sociodemographic characteristics and medical history
Délai: Pre-intervention (baseline)
|
Sociodemographic data will be collected to characterize the study population, including age, gender, level of education, employment status, physical activity level, and substance use (alcohol, tobacco, and drugs). Participants' medical history and current medication use will be recorded to characterize baseline health status and control for potential confounding factors in analyses. |
Pre-intervention (baseline)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Nicolas Lejeune, University of Liege - CHU Liege
- Chaise d'étude: Géraldine Martens, University of Liege
- Directeur d'études: Fanny Montulet, University of Liege
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- Stim-PPCS : 2026-183
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data will be made available to qualified researchers whose requests are methodologically sound and for legitimate scientific purposes, following publication of the primary study results.
Délai de partage IPD
IPD and supporting information will be made available after publication of the primary study results upon reasonable request and subject to approval. Data will be stored in Dataverse ULiège under restricted access for an indefinite period.
Critères d'accès au partage IPD
Access to the anonymized individual participant data (IPD) and supporting information, including the study protocol, data dictionary, and statistical analysis code, will be granted to qualified researchers upon reasonable request.
Requests will be evaluated by the principal investigator based on scientific validity, methodological quality, and compliance with the original ethical approval and informed consent.
Approved users will receive access through a secure institutional repository (e.g., ULiège Dataverse)
Only de-identified data will be shared.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .